Please login to the form below

Not currently logged in
Email:
Password:

Ono Pharmaceutical

This page shows the latest Ono Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Forxiga approved in Japan for the treatment of CKD

AstraZeneca’s Forxiga approved in Japan for the treatment of CKD

Ono Pharmaceutical has distribution rights for Forxiga in Japan and will co-promote the drug for the treatment of CKD along with AstraZeneca.

Latest news

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Clearly on a roll with Japan, X-Chem has also signed a deal with Ono Pharmaceutical covering oncology targets. ... 190. Ambest Pharmaceutical. Sihuan Pharmaceutical. Acquisition. Manufacturing of injectables. 160. X-Chem.

  • Deal Watch July 2016 Deal Watch July 2016

    In the second immuno-therapy deal to make the top 20 this month ONO Pharmaceuticals paid $12.5m upfront for the rights to develop Celyad's phase I product, allogeneic ... Acquisition. 325. Celyad/ ONO Pharmaceutical. Allogeneic NKR-2 T-cell immunotherapy.

  • Pharma deals during July 2014 Pharma deals during July 2014

    tremelimumab. Existing partners Bristol-Myers Squibb (BMS) and Ono Pharmaceutical also announced that they will jointly develop and commercialise multiple immunotherapies as single and combination treatments.

  • Pharma deals during August 2013 Pharma deals during August 2013

    Onyx has sole marketing rights with the exception of Japan where it is licensed to Ono Pharmaceutical. ... the UK pharmaceutical market (11 per cent sales growth over the previous year) and will clearly strengthen Stada Arzneimittel's UK footprint.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
How scientific storytelling can help Pharma cut through the noise
Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...